MXPA05010388A - Dispositivos, metodos y composiciones para prevenir la restenosis. - Google Patents

Dispositivos, metodos y composiciones para prevenir la restenosis.

Info

Publication number
MXPA05010388A
MXPA05010388A MXPA05010388A MXPA05010388A MXPA05010388A MX PA05010388 A MXPA05010388 A MX PA05010388A MX PA05010388 A MXPA05010388 A MX PA05010388A MX PA05010388 A MXPA05010388 A MX PA05010388A MX PA05010388 A MXPA05010388 A MX PA05010388A
Authority
MX
Mexico
Prior art keywords
compositions
methods
devices
prevent restenosis
rapamycin
Prior art date
Application number
MXPA05010388A
Other languages
English (en)
Inventor
Robert G Johnson Jr
Original Assignee
Kosan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kosan Biosciences Inc filed Critical Kosan Biosciences Inc
Publication of MXPA05010388A publication Critical patent/MXPA05010388A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A61F2/07—Stent-grafts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Dispositivos medicos, composiciones y metodos para prevenir o reducir la restenosis utilizando epotilonas, analogos de geldanamicina y rapamicina o analogos de rapamicina solos o en combinaciones sinergisticas.
MXPA05010388A 2003-03-28 2004-03-29 Dispositivos, metodos y composiciones para prevenir la restenosis. MXPA05010388A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45852103P 2003-03-28 2003-03-28
US49009803P 2003-07-24 2003-07-24
PCT/US2004/010212 WO2004087045A2 (en) 2003-03-28 2004-03-29 Devices, methods, and compositions to prevent restenosis

Publications (1)

Publication Number Publication Date
MXPA05010388A true MXPA05010388A (es) 2006-03-08

Family

ID=33135102

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010388A MXPA05010388A (es) 2003-03-28 2004-03-29 Dispositivos, metodos y composiciones para prevenir la restenosis.

Country Status (10)

Country Link
US (1) US20050002983A1 (es)
EP (1) EP1608289A2 (es)
JP (1) JP2006523235A (es)
KR (1) KR20050119665A (es)
AU (1) AU2004226350A1 (es)
BR (1) BRPI0408891A (es)
CA (1) CA2518872A1 (es)
MX (1) MXPA05010388A (es)
RU (1) RU2005133199A (es)
WO (1) WO2004087045A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
CA2496477C (en) 2002-08-23 2012-10-16 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
CA2545457A1 (en) * 2003-11-12 2005-06-23 Kosan Biosciences, Inc. 11-o-methylgeldanamycin compounds
CA2598239C (en) * 2005-02-18 2019-10-29 Abraxis Bioscience, Inc. Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
US7910152B2 (en) * 2006-02-28 2011-03-22 Advanced Cardiovascular Systems, Inc. Poly(ester amide)-based drug delivery systems with controlled release rate and morphology
US20080039362A1 (en) * 2006-08-09 2008-02-14 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
KR100860326B1 (ko) * 2007-06-01 2008-09-25 충북대학교 산학협력단 에포틸론 ｂ를 함유하는 혈관재협착 예방 및 치료제
JP6242213B2 (ja) 2010-03-29 2017-12-06 アブラクシス バイオサイエンス， エルエルシー 薬物送達および治療用薬剤の有効性を向上させる方法
KR101894689B1 (ko) 2010-03-29 2018-09-04 아브락시스 바이오사이언스, 엘엘씨 암의 치료 방법
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
CN100998565A (zh) * 1993-07-19 2007-07-18 血管技术药物公司 抗血管生长组合物及使用方法
DE69434598T3 (de) * 1993-07-29 2010-07-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Verwendung von Paclitaxel und seinen Derivaten zur Herstellung eines Medikaments für die Behandlung von Restenose
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6242469B1 (en) * 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6884429B2 (en) * 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
US8029561B1 (en) * 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
US6419692B1 (en) * 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
ES2283344T3 (es) * 1999-10-29 2007-11-01 Kosan Biosciences, Inc. Analogos de la rapamicina.
US6899731B2 (en) * 1999-12-30 2005-05-31 Boston Scientific Scimed, Inc. Controlled delivery of therapeutic agents by insertable medical devices
JP4583756B2 (ja) * 2000-10-31 2010-11-17 クック インコーポレイテッド 医療器具
US20030050692A1 (en) * 2000-12-22 2003-03-13 Avantec Vascular Corporation Delivery of therapeutic capable agents
US6893859B2 (en) * 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US20020127263A1 (en) * 2001-02-27 2002-09-12 Wenda Carlyle Peroxisome proliferator-acitvated receptor gamma ligand eluting medical device
US20030023082A1 (en) * 2001-05-15 2003-01-30 Gary Ashley Epothilone derivatives and methods for making and using the same
WO2003013430A2 (en) * 2001-08-06 2003-02-20 Kosan Biosciences, Inc. Benzoquinone ansamycins
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US6641611B2 (en) * 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
WO2003034944A1 (de) * 2001-10-15 2003-05-01 Hemoteq Gmbh Beschichtung von stents zur verhinderung von restenose
US7473273B2 (en) * 2002-01-22 2009-01-06 Medtronic Vascular, Inc. Stent assembly with therapeutic agent exterior banding
AU2003220390A1 (en) * 2002-03-18 2003-10-08 Medtronic Ave Inc. Medical devices for delivering anti-proliferative compositions to anatomical sites at risk for restenosis
US20030187493A1 (en) * 2002-03-29 2003-10-02 Todd Campbell Coated stent with protective assembly and method of using same
US7470281B2 (en) * 2002-04-26 2008-12-30 Medtronic Vascular, Inc. Coated stent with crimpable coating
US7097850B2 (en) * 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
DK1521603T3 (da) * 2002-07-12 2011-04-18 Cook Inc Coated medicinsk anordning
US6786922B2 (en) * 2002-10-08 2004-09-07 Cook Incorporated Stent with ring architecture and axially displaced connector segments
EP2135867B1 (en) * 2002-11-07 2013-09-25 Kosan Biosciences Incorporated Trans-9, 10-dehydroepothilone C and trans-9, 10-dehydroepothilone D, analogs thereof and methods of making the same
US20040172127A1 (en) * 2002-12-09 2004-09-02 John Kantor Modular stent having polymer bridges at modular unit contact sites
JP2006516548A (ja) * 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
US20040243214A1 (en) * 2003-04-23 2004-12-02 Medtronic Vascular, Inc. Coated stent with protective packaging and method of using same

Also Published As

Publication number Publication date
BRPI0408891A (pt) 2006-04-11
AU2004226350A1 (en) 2004-10-14
WO2004087045A3 (en) 2005-07-21
EP1608289A2 (en) 2005-12-28
US20050002983A1 (en) 2005-01-06
RU2005133199A (ru) 2006-02-10
KR20050119665A (ko) 2005-12-21
WO2004087045A2 (en) 2004-10-14
CA2518872A1 (en) 2004-10-14
JP2006523235A (ja) 2006-10-12

Similar Documents

Publication Publication Date Title
PL1646634T3 (pl) Zastosowanie rapamycyny i pochodnych rapamycyny w leczeniu utraty kości
MXPA06000123A (es) Suspension aislante de apoyo central de resorte rapido de plastico y metodo para fabricar y ensamblar el mismo.
TW200637522A (en) Skin treatment articles and methods
TW200718689A (en) 2-Amino-quinazolin-5-ones
IL174637A0 (en) Fibrosis-inducing agents, compositions containing the same and medical implants containing the same
SG145695A1 (en) Pyridyl derivatives and their use as therapeutic agents
SG145700A1 (en) Pyridyl derivatives and their use as therapeutic agents
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
IL175300A0 (en) Indirubin-type compounds, compositions, and methods for their use
IL180551A0 (en) Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines in the treatment of nausea and vomiting
MX2008007808A (es) Analogos de rifamicina y usos de ellos.
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
TW200716088A (en) Formulations and methods for treating amyloidosis
SG10201704913RA (en) Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
TW200700071A (en) Novel use
AU2003223731A1 (en) Methods for sterilizing tissues using cryopreservatives
HK1121936A1 (en) Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
AU2006321904A8 (en) 1, 1, 3-trioxo-1 , 2 , 5-thiadiazolidines and their use as PTP-ases inhibitors
TNSN07240A1 (en) Compounds for flaviviridae treatment
MXPA05010388A (es) Dispositivos, metodos y composiciones para prevenir la restenosis.
ZA200706662B (en) Haloaryl substituted Aminopurines, compositions thereof, and methods of treatment therewith
MX2007002917A (es) Todo-trans-retinol: todo-trans-13, 14-dihidrorretinol saturasa y metodos de uso de la misma.
TWI372047B (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
HK1111924A1 (en) Depigmenting or brightening cosmetic composition comprising at least one oxazolin as an active ingredient
HUP0300990D0 (en) Synergistic combination for the prophylaxis and treatment of diabetes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal